These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 39097726)

  • 1. Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.
    Jin Y; Wang X; Chen K; Chen Y; Zhou L; Zeng Y; Zhou Y; Pan Z; Wang D; Li Z; Liang Y; Ling W; Li D
    Lipids Health Dis; 2024 Aug; 23(1):239. PubMed ID: 39097726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silymarin targets the FXR protein through microbial metabolite 7-keto-deoxycholic acid to treat MASLD in obese mice.
    Yi M; Manzoor M; Yang M; Zhang H; Wang L; Zhao L; Xiang L; Qi J
    Phytomedicine; 2024 Oct; 133():155947. PubMed ID: 39178642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
    Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
    Metab Syndr Relat Disord; 2024 Oct; 22(8):608-618. PubMed ID: 38868900
    [No Abstract]   [Full Text] [Related]  

  • 4. Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial.
    He Y; Chen X; Li Y; Liang Y; Hong T; Yang J; Cao Z; Mai H; Yao J; Zhang T; Wu K; Zou J; Feng D
    Am J Clin Nutr; 2024 Jul; 120(1):66-79. PubMed ID: 38795741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial.
    Vrentzos E; Ikonomidis I; Pavlidis G; Katogiannis K; Korakas E; Kountouri A; Pliouta L; Michalopoulou E; Pelekanou E; Boumpas D; Lambadiari V
    Cardiovasc Diabetol; 2024 Jul; 23(1):245. PubMed ID: 38987784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.
    Park IG; Yoon SJ; Won SM; Oh KK; Hyun JY; Suk KT; Lee U
    Sci Rep; 2024 Jul; 14(1):16122. PubMed ID: 38997279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
    Stefan N; Hartleb M; Popovic B; Varona R
    Trials; 2024 Jun; 25(1):374. PubMed ID: 38858768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials.
    Wu J; Chen X; Qian J; Li G
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102397. PubMed ID: 38879003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily Orange Consumption Reduces Hepatic Steatosis Prevalence in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: Exploratory Outcomes of a Randomized Clinical Trial.
    Notarnicola M; Tutino V; De Nunzio V; Cisternino AM; Cofano M; Donghia R; Giannuzzi V; Zappimbulso M; Milella RA; Giannelli G; Fontana L
    Nutrients; 2024 Sep; 16(18):. PubMed ID: 39339791
    [No Abstract]   [Full Text] [Related]  

  • 10. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
    Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
    Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial.
    Perva IT; Simina IE; Bende R; Motofelea AC; Chirita Emandi A; Andreescu N; Sima A; Vlad A; Sporea I; Zimbru C; Tutac PC; Puiu M; Niculescu MD
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202647
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial.
    Ebrahimpour-Koujan S; Sohrabpour AA; Giovannucci E; Vatannejad A; Esmaillzadeh A
    Nutr J; 2024 Feb; 23(1):24. PubMed ID: 38413933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial.
    Simon TG; Wilechansky RM; Stoyanova S; Grossman A; Dichtel LE; Lauer GM; Miller KK; Hoshida Y; Corey KE; Loomba R; Chung RT; Chan AT
    JAMA; 2024 Mar; 331(11):920-929. PubMed ID: 38502074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplementation of Silymarin Alone or in Combination with Salvianolic Acids B and Puerarin Regulates Gut Microbiota and Its Metabolism to Improve High-Fat Diet-Induced NAFLD in Mice.
    Wang X; Jin Y; Di C; Zeng Y; Zhou Y; Chen Y; Pan Z; Li Z; Ling W
    Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease.
    Martínez-Sanz J; Talavera-Rodríguez A; Díaz-Álvarez J; Rosas Cancio-Suárez M; Rodríguez JM; Alba C; Montes ML; Martín-Mateos R; Burgos-Santamaría D; Moreno S; Serrano-Villar S; Sánchez-Conde M
    Front Immunol; 2023; 14():1297378. PubMed ID: 38162648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
    Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
    Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis.
    Qin D; Pan P; Lyu B; Chen W; Gao Y
    Biomed Pharmacother; 2024 Aug; 177():116942. PubMed ID: 38889641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective study.
    Nixdorf L; Hartl L; Ströhl S; Felsenreich DM; Mairinger M; Jedamzik J; Richwien P; Mozayani B; Semmler G; Balcar L; Schwarz M; Jachs M; Dominik N; Bichler C; Trauner M; Mandorfer M; Reiberger T; Langer FB; Bauer DJM; Prager G
    Sci Rep; 2024 Jul; 14(1):17558. PubMed ID: 39080285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutraceutical blends predict enhanced health via microbiota reshaping improving cytokines and life quality: a Brazilian double-blind randomized trial.
    Santamarina AB; de Freitas JA; Franco LAM; Nehmi-Filho V; Fonseca JV; Martins RC; Turri JA; da Silva BFRB; Fugi BEI; da Fonseca SS; Gusmão AF; Olivieri EHR; de Souza E; Costa S; Sabino EC; Otoch JP; Pessoa AFM
    Sci Rep; 2024 May; 14(1):11127. PubMed ID: 38750102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.